Skip to main content

Table 4 Parameters

From: The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19

Parameter

Presentation

Test

PVPi (days 1, 2, 4, and 7)

Mean ± SD

Linear mixed model

Oxygenation index (days 1, 2, 4, 7, 10, and 28)

Mean ± SD

Linear mixed model

PaO2/FiO2 ratio (days 1, 2, 4, 7, 10, and 28)

Mean ± SD

Linear mixed model

Airway driving pressure (days 1, 2, 4, 7, 10, and 28)

Mean ± SD

Linear mixed model

Compliance (days 1, 2, 4, 7, 10, and 28)

Mean ± SD

Linear mixed model

Mechanical power (days 1, 2, 4, 7, 10, and 28)

Mean ± SD

Linear mixed model

SOFA score (days 1, 2, 4, 7, 10, and 28)

Mean ± SD

Linear mixed model

Number of ventilator-free days (days 1 to 28)

Mean ± SD

T-test

Duration of mechanical ventilation (days) (days 1 to 28)

Mean ± SD

T-test

Length of ICU stay (days) (days 1 to 28)

Mean ± SD

T-test

Hospital length of stay (days) (days 1 to 28)

Mean ± SD

T-test

28-day mortality

Number (%)

Cox prop. Hazards

Plasma biomarkers (days 1, 2, 4, 7, and 10)

Median ± IQR

MWU / Linear mixed model

Blood cell counts (days 1, 2, 4, 7, and 10)

  

RBC

Mean ± SD

Linear mixed model

WBC

Mean ± SD

Linear mixed model

Thrombocytes

Mean ± SD

Linear mixed model

Kidney function (days 1, 2, 4, 7, and 10)

  

Creatinine

Mean ± SD

Linear mixed model

eGFR

Mean ± SD

Linear mixed model

Liver enzymes (days 1, 2, 4, 7, and 10)

  

ALT

Mean ± SD

Linear mixed model

AST

Mean ± SD

Linear mixed model

Bilirubin

Mean ± SD

Linear mixed model

γ-glutamyl transferase

Mean ± SD

Linear mixed model

Alkaline phosphatase

Mean ± SD

Linear mixed model

NT-proBNP (days 1, 2, 4, 7, and 10)

Median ± IQR

Linear mixed model

SAEs / AE

Number (%)

Descriptive

ECG (ΔQTc time day 1 versus day 4)

Mean ± SD

T-test